US Pharmaceutical giant Moderna on Friday claimed that its COVID-19 vaccine is effective in protecting against infection for six months. The company has issued a statement saying that after the second dose, showed hardly any change from the 94% efficacy reported in its original clinical trial. The efficacy of the vaccine showed 96.2 percent in the first two months after the second dose, which decreases to 83.7 percent after six months.
Meanwhile, the company has said that a booster dose may be required to avoid the delta variant of COVID-19. At the same time, Moderna CEO Stephane Bancel says that three doses of the vaccine are necessary to be safe. He further said, "We are now capacity constrained for 2021. We are not taking any more orders for 2021 delivery. Our COVID-19 vaccine is showing durable efficacy of 93% through six months, but recognize that the Delta variant is a significant new threat so we must remain vigilant."
According to pharma company Biological E, the vaccine trial is likely to complete by September. According to the information received by the sources, this is an RBD protein subunit vaccine, which is currently undergoing Phase III clinical trials. Better results reported about this vaccine in the first and second trials.
Meanwhile, its Phase III clinical trial is currently underway. During the company's MD Mahima Datla's meeting with Union Health Minister Mansukh Mandaviya, he emphasied on production over supply after the vaccine approved for testing and emergency use. The government expects to provide around one crore doses in the first month.
Also Read:
Like and Follow us on :